BioSpace News Archive

OliX Pharmaceuticals, Inc. today announced that the first participant was dosed today with OLX75016.

BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, announced today the completion of an oversubscribed Series D financing round of $170 million led by Sofinnova Investments.

DermTech, Inc. will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company’s fourth-quarter 2023 operating and financial results.

Perrigo Company plc today announced that it plans to issue its fourth quarter and fiscal year 2023 financial results on Tuesday, February 27th , 2024 and will host a conference call beginning at 8:30 A.M. (EST).

Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq: MRVI), announced today a strategic partnership for the quantification of Host Cell Proteins (“HCP”) from the proprietary and patented C1-cells filamentous fungus Thermothelomyces heterothallica, (formerly Myceliophthora thermophila).

Eyebiotech Limited (“EyeBio” or “the Company”) announced today the presentation of Week 12 data from its first-in-human Phase 1b/2a AMARONE trial of Restoret in patients with treatment-naïve diabetic macular edema (DME) and treatment-naïve neovascular age-related macular degeneration (NVAMD).

ValGenesis Inc., the market leader in enterprise validation lifecycle management systems, and RxCloud, a specialized consulting and systems integration organization, have entered into a strategic partnership to address quality assurance and compliance challenges in life sciences.

GeoVax Labs, Inc. announced multiple actions by global patent offices strengthening the Company’s intellectual property assets.

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced it is highlighting recently-launched products in high growth segments of joint preservation and restoration from its Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions businesses during the 2024 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting on February 13-15 in San Francisco, CA.

Trinity Biotech Plc. announced that it plans to change the ratio of the American depositary shares representing its Class A ordinary shares from one ADS representing four Class A ordinary share to one ADS representing twenty Class A ordinary shares.